Theravance Biopharma Inc. (NASDAQ:TBPH) dropped 1.5% during trading on Monday . The stock traded as low as $22.99 and last traded at $23.19, with a volume of 57,800 shares traded. The stock had previously closed at $23.55.

TBPH has been the subject of several research analyst reports. Leerink Swann upped their price target on Theravance Biopharma to $29.00 and gave the stock an “outperform” rating in a research note on Monday, June 20th. Zacks Investment Research upgraded Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research note on Tuesday, July 12th. Guggenheim initiated coverage on Theravance Biopharma in a research note on Monday, June 20th. They set a “buy” rating and a $30.00 price target for the company. Finally, Bank of America Corp. lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Thursday, May 5th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $24.75.

The stock’s 50 day moving average price is $22.99 and its 200-day moving average price is $19.41. The company’s market capitalization is $1.08 billion.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.14. The firm earned $18.40 million during the quarter, compared to analyst estimates of $18.69 million. Equities research analysts expect that Theravance Biopharma Inc. will post ($4.24) EPS for the current year.

An institutional investor recently raised its position in Theravance Biopharma stock. OppenheimerFunds Inc. increased its stake in Theravance Biopharma Inc. (NASDAQ:TBPH) by 1.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,103,485 shares of the biopharmaceutical company’s stock after buying an additional 12,120 shares during the period. OppenheimerFunds Inc. owned 2.92% of Theravance Biopharma worth $18,086,000 as of its most recent filing with the SEC.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.